Back to search results

MitoQ for Preeclampsia

This study is looking at whether a dietary supplement called Mitoquinol Mesylate (MitoQ) can help improve blood vessel function in pregnant patients with preeclampsia. Preeclampsia is a serious condition during pregnancy that can affect both the mother and baby. Researchers believe that MitoQ, which is a mitochondrial-antioxidant, might help restore how blood vessels relax and improve how the placenta works. This could potentially help prolong pregnancy. You might be able to join if you are a pregnant woman between 18 and 50 years old, have been diagnosed with preeclampsia with severe features, and are between 23 and 32 weeks pregnant with a single baby. The main goal is to see if MitoQ improves how your brachial artery (a major artery in your arm) dilates. The study's current status is unclear, and it plans to enroll 80 participants.

Study design
This is an interventional study where participants will be randomly assigned to receive either Mitoquinol Mesylate or a placebo. The study plans to enroll 80 participants.
What's involved
If you participate, you would take one capsule daily (either Mitoquinol Mesylate or a placebo) from when you join the study until you deliver your baby. Your brachial artery flow-mediated dilation (FMD) will be measured 1-2 times per week during this period.
Compensation
Not stated in the trial record.
Follow-up
Your brachial artery flow-mediated dilation (FMD) will be measured until delivery, for up to 10 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07229261

MitoQ to Improve Vascular Funciton in Preeclampsia

Recruiting
NAAges 18–50InterventionalTreatment
Medical College of Wisconsin
~80 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:Mitoquinol MesylatePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Brachial Artery Flow Mediated Dilation (FMD)
Measured over 1-2 times per week from enrollment until delivery, up to 10 months

Conditions

Preeclampsia
Pregnancy

Explore related trials

Preeclampsia

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Jennifer J McIntosh, D.O., · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin

Who to contact

Jennifer McIntosh, D.O., M.S.
[email protected]
14148059019
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Inpatient Cohort
pregnant patients with a clinical diagnosis of preeclampsia with severe features
gestational age between 23+0 and 32+0 weeks' gestation
singleton pregnancy
age 18-50 years old
No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features
Able to consent and follow a 2-step commend
English speaking
Outpatient Cohort
Pregnant patients with a clinical diagnosis of preeclampsia without severe features
gestational age between 23+0 and 34+0 weeks' gestation
singleton pregnancy
age 18-50 years old
No indication for immediate delivery
Planned outpatient management of preeclampsia
Able to consent and follow a 2-step commend
English speaking

Exclusion

• Unable to stand from chair without physical assistance from another person (able to use assistive device).
History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg).
Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization)
History of head trauma or concussion within the past 6 months
Comorbid neurological disorder
Peripheral vascular disease
Diagnosed myocardial infarction or arrhythmia in the previous year
Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg
Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator

What this trial measures

  • Brachial Artery Flow Mediated Dilation (FMD)1-2 times per week from enrollment until delivery, up to 10 months

    We will measure brachial artery vascular health in the arm. Baseline brachial artery diameter and blood flow velocity through the artery will be measured before and after a pneumatic forearm cuff is inflated to 225 mmHg for five minutes.